📰 Recommended Phase News
Page 3 - Recommended Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recommended Phase. Real-time updates on events, politics, business and more.
May 11, 2023
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction Overall... | May 11, 2023
May 11, 2023
Item 8.01Other Events. On May 11, 2023, Olema Pharmaceuticals, Inc. announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Companys complete estrogen receptor ... | May 11, 2023
March 14, 2023
Operator: Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call. Please note, this event is being recorded.
March 13, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
March 8, 2023
Operator: Welcome to the Immuneering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
February 17, 2023
17.02.2023 - Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) - Oryzon Genomics, S.A. (ISIN ...
January 7, 2023
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...
January 6, 2023
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...
January 4, 2023
/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel,...
December 9, 2022
/PRNewswire/ -- Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2...